Navigation Links
PDL BioPharma Announces Two $0.50 Dividends in 2010
Date:1/28/2010

INCLINE VILLAGE, Nev., Jan. 28 /PRNewswire-FirstCall/ -- PDL BioPharma, Inc. (PDL) (Nasdaq: PDLI) today announced that it will pay two special dividends to its stockholders in 2010. Each of the dividends will be $0.50 per share. The first special dividend will be paid on April 1, 2010 to all stockholders who own shares of PDL on March 15, 2010, the Record Date. The second special dividend will be paid on October 1, 2010 to all stockholders who own shares of PDL on September 15, 2010, the Record Date.

Stockholders desiring to purchase shares with rights to the special dividend must ensure that their trades are executed prior to the "ex-dividend" date and settle prior to the Record Date. NASDAQ will establish an ex-dividend date that is generally three business days prior to the Record Date. You should consult with your broker or financial advisor regarding your specific situation.

About PDL BioPharma

PDL pioneered the humanization of monoclonal antibodies and, by doing so, enabled the discovery of a new generation of targeted treatments for cancer and immunologic diseases. PDL is focused on maximizing the value of its antibody humanization patents and related assets. The Company receives royalties on sales of a number of humanized antibody products marketed today based on patents which expire in late 2014. For more information, please visit www.pdl.com.

NOTE: PDL BioPharma and the PDL BioPharma logo are considered trademarks of PDL BioPharma, Inc.

Forward-looking Statements

As all dividend payments are subject to compliance with legal requirements, dividend announcements constitute "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Important factors that could impair the value of the Company's royalty assets and limit the Company's ability to pay dividends are disclosed in the risk factors contained in the Company's 2008 Annual Report on Form 10-K filed with the Securities and Exchange Commission on March 2, 2009. All forward-looking statements are expressly qualified in their entirety by such factors. We do not undertake any duty to update any forward-looking statement except as required by law.

SOURCE PDL BioPharma

RELATED LINKS
http://www.pdl.com

'/>"/>

SOURCE PDL BioPharma
Copyright©2010 PR Newswire.
All rights reserved

Related medicine news :

1. Therapure Biopharma Inc. Commissions its Commercial-Scale Lyophilizer
2. Microbix and Therapure Biopharma Form Partnership to Expand Water-Based Supplies to the Pharma Industry
3. Seven More Biopharmaceutical Research Companies Join PhRMA
4. BioProcess International Launches a New and Improved Website for Biopharmaceutical Managers and Scientists
5. Therapure Biopharma Inc. and YM BioSciences Inc. Announce Partnership
6. Therapure Biopharma Inc. and Akorn, Inc. Announce Strategic Supply Contract
7. Securities Class Action Filed by Shepherd, Finkelman, Miller & Shah, LLP on Behalf of Hemispherx Biopharma Securities Purchasers Between February 18, 2009 and November 2, 2009
8. Leading Biopharmaceutical Company Selects Stimar for Code of Conduct Regulation Training
9. OTCBB-WNDM Announces Activation of BioPharma Division to Solicit Technology and Development Partners
10. Therapure Biopharma Inc. Announces Delivery of its First Commercial-Scale Lyophilizer
11. Surviving Healthcare Reform: How Biopharma Companies Can Come Out on Top
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/19/2017)... ... 2017 , ... The Davidson Institute for Talent Development will ... 27 at a reception in Washington D.C. The recipients received $50,000, $25,000 and ... “I am honored to be a Davidson Fellow Laureate,” said Rishab Gargeya, a ...
(Date:9/19/2017)... Brook, IL (PRWEB) , ... September 19, 2017 ... ... are significantly and positively linked to the Certified Emergency Nurse (CEN®) certification ... for Emergency Nursing (BCEN). The value of certification study, conducted by the Human ...
(Date:9/18/2017)... (PRWEB) , ... September 19, 2017 , ... ... Asia Pacific’s protein ingredient market , expected to grow at the fastest CAGR ... Sullivan sharing the ‘Global Food Protein Trends & Growth Opportunities in Asia’ – ...
(Date:9/18/2017)... ... September 18, 2017 , ... ... the finance role on the executive team adding a Chief Financial Officer following ... independent company. This expansion will support the strategic growth strategy Aegis has defined ...
(Date:9/18/2017)... Fort Lee, NJ (PRWEB) , ... September 18, 2017 , ... ... state’s history, CareOne, a New jersey based company, has launched an aid effort focused ... Irma as it battered the state over two days and left thousands homeless and ...
Breaking Medicine News(10 mins):
(Date:9/13/2017)...   OrthoAtlanta has been named the official orthopedic ... (AFHC) for the 2018 College Football Playoff (CFP) National Championship ... Stadium in Atlanta, Georgia . OrthoAtlanta is ... campaign, participating in many activities leading up to, and including ... ...
(Date:9/12/2017)... Sept. 12, 2017  ValGenesis Inc., the global ... is pleased to announce the appointment of Dr. ... its Board of Directors and Chairman of Advisory ... life science companies to manage their entire validation ... paper in this process. Furthermore, ValGenesis VLMS enables ...
(Date:9/9/2017)... 2017  Eli Lilly and Company (NYSE: ... data for lasmiditan, an investigational, oral, first-in-class molecule for ... improvements compared to placebo in the Phase 3 SPARTAN ... 18th Congress of the International Headache Society (IHC) in ... presented today demonstrate lasmiditan,s potential to reduce pain and ...
Breaking Medicine Technology: